Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

3 results

  • 8 - Colloid Fluids

  • from Section 2 - Basic Science & Concepts in Fluid Therapy
    • By
  • Edited by Alexandre Joosten, University of California, Los Angeles, Maxime Cannesson, University of California, Los Angeles, Robert G. Hahn, Karolinska Institutet, Stockholm
  • Book:
    Hemodynamic Monitoring and Fluid Therapy during Surgery
    Published online:
    11 April 2024
    Print publication:
    02 May 2024, pp 87-95

  • Summary

    Colloid fluids are crystalloid electrolyte solutions with a macromolecule added that binds water by its colloid osmotic pressure. As macromolecules escape the plasma only with difficulty, the resulting plasma volume expansion is strong and lasts many hours. The clinically used colloid fluids include albumin, hydroxyethyl starch, gelatin, and dextran.

    The plasma volume expansion shows one-compartment kinetics. Marketed iso-oncotic fluids are usually composed so that the infused volume expands the plasma volume by the infused amount. Exceptions include hyperoncotic variants such as 20% albumin.

    The main indication for colloid fluid is as second-line treatment of hemorrhage. Because of inherent allergic properties, crystalloid electrolyte fluids should be used when the hemorrhage is small. A changeover to a colloid should be performed only when the crystalloid volume is so large that adverse effects may ensue. The only other clinical indication is that dextran can be prescribed to improve microcirculatory flow.

  • Non-steroid, non-antibiotic anti-biofilm therapy for the treatment of chronic rhinosinusitis: a systematic review

  • A Taylor, J Fuzi, A Sideris, C Banks, T E Havas
  • Journal:
    The Journal of Laryngology & Otology / Volume 135 / Issue 3 / March 2021
    Published online by Cambridge University Press:
    05 March 2021, pp. 196-205
    Print publication:
    March 2021
  • Objective

    Chronic rhinosinusitis patients with biofilms cultured from their sinonasal cavity have greater symptom burden and risk of recalcitrant disease. A number of non-antibiotic, ‘anti-biofilm’ treatments exist which show anti-biofilm properties in preclinical studies. There is little evidence evaluating their impact on clinical symptom scores in chronic rhinosinusitis.

    Method

    A systematic review was performed to assess the literature regarding the efficacy of non-steroid, non-antibiotic, anti-biofilm specific topical therapies in the treatment of chronic rhinosinusitis. The primary outcome assessed was change in validated patient reported outcome measures before and after anti-biofilm treatment.

    Results

    Thirteen studies assessing the effect of anti-biofilm therapies in chronic rhinosinusitis through validated patient-reported outcome measures were included. Seven different anti-biofilm specific therapies for chronic rhinosinusitis were identified. None of the seven anti-biofilm therapies was identified as being confidently efficacious beyond placebo. Only one therapy (intranasal xylitol) showed a statistically significant reduction in symptom scores compared with placebo in more than one trial.

    Conclusion

    Robust evidence supporting the use of various anti-biofilm therapies in chronic rhinosinusitis is lacking. Further high quality, human, in vivo trials studying the effect of anti-biofilm therapies in chronic rhinosinusitis are needed to address the deficiencies of the current evidence base.

  • Temperament profiles, major depression, and response to treatment with SSRIs in psychiatric outpatients☆

  • O. Kampman, O. Poutanen, A. Illi, E. Setälä-Soikkeli, M. Viikki, T. Nuolivirta, E. Leinonen
  • Journal:
    European Psychiatry / Volume 27 / Issue 4 / May 2012
    Published online by Cambridge University Press:
    15 April 2020, pp. 245-249
  • Objective

    The Temperament and Character Inventory (TCI) is commonly used in adult populations. Our aim was to explore: (1) if there are specific differences in temperament dimensions related to depression in comparison with general population, (2) if the treatment response during the acute phase of major depressive disorder (MDD) is predictable by TCI temperament dimensions.

    Method

    Temperament profiles in 98 MDD patients were compared with a Finnish community sample. The patients were treated with serotonin selective reuptake inhibitors (SSRIs) for 6weeks and their temperament profiles were assessed at baseline and endpoint. The harm avoidance (HA) and depression scores at baseline and endpoint were modelled with path analysis. For path modelling, we tested the relationships between different temperament dimensions and depression symptoms and other clinical variables with Mancova model.

    Results

    The HA scores were significantly higher in patients both at baseline and endpoint compared to the Northern Finland 1966 Birth Cohort (NFBC). The patients, and especially males, had slightly higher reward dependency (RD) scores. HA at endpoint explained moderately the Montgomery Åsberg Depression Rating Scale (MADRS) endpoint score. HA endpoint score was strongly explained by HA baseline score.

    Conclusions

    HA is associated with risk of and treatment response to depression.